Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan C P Roos

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal of Cataract and Refractive Surgery|December 13, 2005
Use of trypan blue for penetrating keratoplastyJonathan C P Roos, Malcolm G Kerr Muir
The Journal of Rheumatology|January 12, 2007
Neurological complications of infliximabJonathan C P Roos, Andrew J K Ostor
Eye (London, England)|November 8, 2018
Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomyJonathan C P Roos, Vignesh Paulpandian, Rachna Murthy
Ophthalmic Plastic and Reconstructive Surgery|November 25, 2020
Inhibition of Fibrotic Contraction by Sirolimus (Rapamycin) in an Ex Vivo Model of Thyroid Eye DiseaseJonathan C P Roos, Viesturs Eglitis, Rachna Murthy
The New England Journal of Medicine|May 14, 2020
Teprotumumab for Active Thyroid Eye DiseaseJonathan C P Roos, Hanna I Hyry, Rachna Murthy
Current Opinion in Ophthalmology|July 2, 2019
Periocular hyaluronic acid fillers: applications, implications, complicationsRachna Murthy, Jonathan C P Roos, Robert A Goldberg
Eye (London, England)|September 30, 2023
Comment on: Epimax-related ocular surface toxicity (EROST): the Glasgow experienceAmy Gallant Sullivan, Rachna Murthy, Jonathan C P Roos
BMJ (Clinical Research Ed.)|November 18, 2010
Orphan drug pricing may warrant a competition law investigationJonathan C P Roos, Hanna I Hyry, Timothy M Cox
Current Medical Research and Opinion|January 20, 2017
Brexit and rare diseases: big risk, bigger opportunity?Hanna I Hyry, Timothy M Cox, Jonathan C P Roos
Cutaneous and Ocular Toxicology|November 17, 2010
Necrotizing group A streptococcal periorbital infection following adalimumab therapy for rheumatoid arthritisJonathan C P Roos, Cornelius René, Andrew J K Ostor
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Cataract and Refractive Surgery|December 13, 2005
Use of trypan blue for penetrating keratoplastyJonathan C P Roos, Malcolm G Kerr Muir
The Journal of Rheumatology|January 12, 2007
Neurological complications of infliximabJonathan C P Roos, Andrew J K Ostor
Eye (London, England)|November 8, 2018
Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomyJonathan C P Roos, Vignesh Paulpandian, Rachna Murthy
Ophthalmic Plastic and Reconstructive Surgery|November 25, 2020
Inhibition of Fibrotic Contraction by Sirolimus (Rapamycin) in an Ex Vivo Model of Thyroid Eye DiseaseJonathan C P Roos, Viesturs Eglitis, Rachna Murthy
The New England Journal of Medicine|May 14, 2020
Teprotumumab for Active Thyroid Eye DiseaseJonathan C P Roos, Hanna I Hyry, Rachna Murthy
Current Opinion in Ophthalmology|July 2, 2019
Periocular hyaluronic acid fillers: applications, implications, complicationsRachna Murthy, Jonathan C P Roos, Robert A Goldberg
Eye (London, England)|September 30, 2023
Comment on: Epimax-related ocular surface toxicity (EROST): the Glasgow experienceAmy Gallant Sullivan, Rachna Murthy, Jonathan C P Roos
BMJ (Clinical Research Ed.)|November 18, 2010
Orphan drug pricing may warrant a competition law investigationJonathan C P Roos, Hanna I Hyry, Timothy M Cox
Current Medical Research and Opinion|January 20, 2017
Brexit and rare diseases: big risk, bigger opportunity?Hanna I Hyry, Timothy M Cox, Jonathan C P Roos
Cutaneous and Ocular Toxicology|November 17, 2010
Necrotizing group A streptococcal periorbital infection following adalimumab therapy for rheumatoid arthritisJonathan C P Roos, Cornelius René, Andrew J K Ostor
Pageof 4